Vaccination against Epstein-Barr virus: current progress and future strategies.

Abstract

A vaccine derived from the high-molecular-weight glycoprotein (gp340) component of the Epstein-Barr (EB) virus membrane antigen conferred complete protection against a 100% lymphomagenic dose of EB virus in the cottontop tamarin, the animal of choice for experiments with EB virus. The membrane-antigen gene has already been cloned, and the development of a… (More)

Topics

Cite this paper

@article{Epstein1986VaccinationAE, title={Vaccination against Epstein-Barr virus: current progress and future strategies.}, author={Marvin A. Epstein}, journal={Lancet}, year={1986}, volume={1 8495}, pages={1425-7} }